Why Should You Attend:
If your job responsibilities require you to have knowledge of Japan’s regulatory requirements, ensuring compliance with regulatory filings and overall GCP, GMP and GLP compliance requirements or understand how best to consider Japan into your Global Business Strategy, then you will profit from attending our training.
This webinar will help you gain a comprehensive understanding of the Regulatory Structure, Clinical Trial Requirements, Marketing Authorization Procedures, Variations Processing, License Renewals and cultural working aspects within the Regulatory Environment in Japan. It will prepare you for regulatory approval processes, Agency meetings, the complexities of running studies in Japan, the importance of partner selection and will also add the cultural knowledge needed for success. The recent changes made by PMDA to be more sponsor and applicant-friendly will be reviewed. Real world experiences on actual interactions with the Agency since these changes were implemented, will also be discussed.
Part I: Japan Regulatory Compliance
Part II: Marketing Authorization Processes – Product Registrations / Licensing
Who will Benefit:
Duration: 90 Minutes
Group-Max. 10 Attendees/Location (For Multiple Locations Contact Customer Care) Super Deal - Get CD/USB Drive Free!
LIVE + RECORDED VERSION
Physical CD-DVD of recorded session will be despatched after 72 hrs on completion of payment
Recorded video session
Robert J. Russell, (Bob) is the President of RJR Consulting, Inc. RJR Consulting Inc. specializes in understanding global regulatory issues for the pharmaceutical industry. Bob has more than 25 years of experience working with FDA and the Commission on technical issues as they relate to policy development, regulation, clinical trial and the medical device development process. Prior to entering the consulting field, Mr. Russell was the Global Director of Regulatory Affairs for two Fortune 100 firms. These companies were major raw material suppliers to the pharmaceutical and medical device industry and one a joint-venture parent of a major pharmaceutical division.